Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 9/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.60 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14720301 | 0.85 | PIK3CB (0.53) | PIK3CBPIK3CDPIK3CAPIK3CGMAPT | |
| SCHEMBL14720173 | 0.85 | PIK3CB (0.43) | PIK3CBPIK3CDPIK3CAPIK3CGTRPV1 | |
| SCHEMBL14720271 | 0.84 | PIK3CB (0.57) | PIK3CBPIK3CDPIK3CAPIK3CGMAPK1 | |
| SCHEMBL14720100 | 0.83 | PIK3CB (0.57) | PIK3CBPIK3CDPIK3CAPIK3CGMAPT | |
| SCHEMBL14720098 | 0.81 | PIK3CB (0.55) | PIK3CBPIK3CDPIK3CAPIK3CGPSD | |
| Acetic Acid SCHEMBL14720443 | 0.81 | PIK3CD (0.51) | PIK3CBPIK3CDPIK3CAPIK3CGMAPT | |
| SCHEMBL15843956 | 0.79 | PIK3CD (0.43) | PIK3CBPIK3CDPIK3CAPIK3CGMAPT | |
| SCHEMBL14722174 | 0.78 | PIK3CB (0.62) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL14720411 | 0.77 | PIK3CB (0.62) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL14720111 | 0.76 | PIK3CB (0.44) | PIK3CBPIK3CDPIK3CAPIK3CGTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096605-B2 | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096605-B2 | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096605-B2 | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140187545-A1 | Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187545-A1 | Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187545-A1 | Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-07-03 | — | — | US | disclosed |
| WO-2013028263-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013028263-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187545-A1 | Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors | PI4KB, PIK3CA, PI4K2B | PIK3CB 6/4885PIK3CD 7/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.